San Francisco—A biochip that detects the presence of even a single tumor cell in blood compares favorably to available methods of identifying colorectal cancer, researchers have found.
The circulating tumor cell (CTC) assay (CellMax Life) had an accuracy of 88% for detecting CRC and 84% for identifying adenomas, investigators from Taiwan reported at the 2018 Gastrointestinal Cancers Symposium (abstract 556).
The researchers evaluated the assay in people known to have CRC or adenomatous